Figure 2.

Kaplan-Meier Estimates of PFS by Investigator Assessment per irRECIST for ICI-Pretreated Patients (A)^a and OS for ICI-Pretreated Patients (B)^b

^aFor PFS, if patients had not experienced disease progression or death, their data was censored at the date of the last available tumor assessment.

^bFor OS, patients who were lost to follow-up or who were alive at the date of data cutoff were censored at the date the patient was last known alive.

CI, confidence interval; ICI, immune checkpoint inhibitor; irRECIST, immune Response Evaluation Criteria In Solid Tumors; OS, overall survival; PFS, progression-free survival; RCC, renal cell carcinoma.